Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference8 articles.
1. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4(6):662–673.
https://doi.org/10.1158/2159-8290.CD-13-0846
2. Gibelin C, Avrillon V, De La Fouchardiere A, Mc Leer-Florin A, Lantuejoul S, Fayette J (2016) Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas. Lung Cancer 102:42–43.
https://doi.org/10.1016/j.lungcan.2016.10.005
3. Zhang Q, Wang J, Zhang S (2015) ALK-rearranged squamous cell lung cancer: a case report. Int J Clin Exp Pathol 8(2):2195–2198
4. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394.
https://doi.org/10.1056/NEJMoa1214886
5. NCCN Clinical Practice Guidelines. Non small cell lung cancer. V3.2018.
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
. Accessed 21 Mar 2018
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献